Accordingly, MG-132 or bortezomib combined with ABT-737 led to enhanced reduction in cell viability, induction of Noxa-dependent apoptosis mediated by activation of Bak/Bax and of caspase-3, and decreased tumor growth in vivo (158,159). This evidence concerns the gene CASP3 and neoplasm.